Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 9, 2014, Pages 1553-1562

  Zittema, Debbie ^a   van den Berg, Else ^a   Meijer, Esther ^a   Boertien, Wendy E ^a   Kobold, Anneke C Muller ^b   Franssen, Casper F M ^a   de Jong, Paul E ^a   Bakker, Stephan J L ^a   Navis, Gerjan ^a   Gansevoort, Ron T ^a  

^a Departments of Nephrology   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; CREATININE; IOTALAMIC ACID I 125; GLYCOPEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; BLOOD; DONOR; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; FEMALE; GLYCOPEPTIDES; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SEVERITY OF ILLNESS INDEX; TISSUE DONORS;

EID: 84923800132     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08690813     Document Type: Article

References (34)

1. Grantham JJ: Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach. Kidney Int 64: 1157–1162, 2003.
2. Meijer E, Boertien WE, Zietse R, Gansevoort RT: Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 34: 235–244, 2011.
3. Hanaoka K, Guggino WB: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 1179–1187, 2000.
4. Meijer E, Gansevoort RT, de Jong PE, van derWal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, vanGoor H, Struck J, de Heer E, Peters DJ: Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease:Optimal timing and dosing of the drug. Nephrol Dial Transplant 26: 2445–2453, 2011.
5. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363–364, 2004.
6. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407–2418, 2012.
7. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5: I129–I138, 1983.
8. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F: Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: Role of premeasurement sample treatment and reference values in children. Clin Chem 45: 98–103, 1999.
9. de Bree FM, Burbach JP: Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol 18: 173–191, 1998.
10. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112–119, 2006.
11. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M: Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92: 3973–3978, 2007.
12. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 361–368, 2011.
13. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP: Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort. Am J Kidney Dis 61: 420–429, 2013.
14. Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT: Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27: 4131–4137, 2012.
15. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL: Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116: 257–263, 2009.
16. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77: 29–36, 2010.
17. Przybylowski P, Malyszko J, Malyszko JS: Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant Proc 42: 1808–1811, 2010.
18. Nigro N, Müller B, Morgenthaler N, Fluri F, Schütz P, Neidert S, Stolz D, Bingisser R, Tamm M, Christ-Crain M, Katan M: The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. Swiss Med Wkly 141: w13270, 2011.
19. Bankir L, Bichet DG: Polycystic kidney disease: An early ureaselective urine-concentrating defect in ADPKD. Nat Rev Nephrol 8: 437–439, 2012.
20. Tent H, Rook M, Stevens LA, van Son WJ, van Pelt LJ, Hofker HS, Ploeg RJ, van der Heide JJ, Navis G: Renal function equations before and after living kidney donation: A within-individual comparison of performance at different levels of renal function. Clin J Am Soc Nephrol 5: 1960–1968, 2010.
21. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824–827, 1994.
22. Donker AJ, van der Hem GK, Sluiter WJ, Beekhuis H: A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 20: 97–103, 1977.
23. Apperloo AJ, de Zeeuw D, Donker AJ, de Jong PE: Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. J Am Soc Nephrol 7: 567–572, 1996.
24. Zietse R, Blankestijn PJ, Pos B, Balk AH, Derkx FH, Weimar W, Schalekamp MA: Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model. Clin Nephrol 43: 29–34, 1995.
25. Michels WM, Grootendorst DC, Rozemeijer K, Dekker FW, Krediet RT: Glomerular filtration rate measurements by 125I-iothalamate should be corrected for inaccurate urine collections with 131I-hippuran. Clin Nephrol 72: 337–343, 2009.
26. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5: 303–311, discussion 312–313, 1989.
27. Rose BD, Post TW: Hyperosmolal States, Hypernatremia. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th Ed., McGraw-Hill Companies, New York, NY 2001.
28. Fazekas AS, Funk GC, Klobassa DS, Rüther H, Ziegler I, Zander R, Semmelrock HJ: Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med 39: 302–308, 2013.
29. Vize PD, Smith HW: A Homeric view of kidney evolution: A reprint of H.W. Smith’s classic essay with a new introduction. Evolution of the kidney. 1943. Anat Rec A Discov Mol Cell Evol Biol 277: 344–354, 2004.
30. Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT: Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 7: 906–913, 2012.
31. Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA: The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4: 1654–1660, 1994.
32. Seeman T, Dusek J, Vondrák K, Bláhová K, Simková E, Kreisinger J, Dvorák P, Kyncl M, Hrìbal Z, Janda J: Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53: 629–634, 2004.
33. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675–680, 1989.
34. Franz KA, Reubi FC: Rate of functional deterioration in polycystic kidney disease. Kidney Int 23: 526–529, 1983.